Skip to main content
    H

    Harrow Health Inc (HROW)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $28.75
    +1.51 (+5.54%)

    Market Cap: $1.02B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    56%(20/36)
    Avg Surprise
    -128.38%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.32
    Range$0.21 - $0.48
    4 analysts
    EPS RevisionsNo revisions (7d)
    0
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$0.36-11.1%
    60d ago$0.38-15.1%
    30d ago$0.27+20.0%
    7d ago$0.320.0%
    Current$0.32
    Revenue Consensus
    $99M
    Range$96M - $102M
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.68
    Range$0.39 - $0.99
    3 analysts
    Revenue Consensus
    $128M
    Range$119M - $133M
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.68---
    Sep 26EST
    		-$0.32---
    Jun 26
    Reported Aug 10
    		$-0.34$-0.23-47.83%Miss-241.7%
    Mar 26
    Reported May 11
    		$-0.74$-0.33-124.24%Miss-94.7%
    Dec 25
    Reported Mar 2
    		$0.27$0.39-31.07%Miss-33.1%
    Sep 25
    Reported Nov 10
    		$0.33$0.29+13.79%Beat+760.0%
    Jun 25
    Reported Aug 11
    		$0.24$0.04+500.00%Beat+500.0%
    Mar 25
    Reported May 8
    		$-0.38$0.01-3900.00%Miss-35.7%
    Dec 24
    Reported Mar 27
    		$0.40$0.13+207.69%Beat+260.0%
    Sep 24
    Reported Nov 13
    		$-0.05$0.07-171.43%Miss+44.4%
    Jun 24
    Reported Aug 7
    		$-0.06$-0.11+45.45%Beat-200.0%
    Mar 24
    Reported May 13
    		$-0.28$-0.25-12.00%Miss-833.3%
    Dec 23
    Reported Mar 19
    		$-0.25$-0.04-525.00%Miss-725.0%
    Sep 23
    Reported Nov 13
    		$-0.09$0.03-400.00%Miss+55.0%
    Jun 23
    Reported Aug 9
    		$-0.02$-0.04+50.00%Beat-300.0%
    Mar 23
    Reported May 11
    		$-0.03$-0.06+50.00%Beat-200.0%
    Dec 22
    Reported Mar 23
    		$0.04N/A+133.33%Beat+114.8%
    Sep 22
    Reported Nov 14
    		$-0.20$-0.03-566.67%Miss-600.0%
    Jun 22
    Reported Aug 9
    		$0.01$0.01+0.00%Beat-88.9%
    Mar 22
    Reported May 5
    		$0.03$-0.04+175.00%Beat-66.7%
    Dec 21
    Reported Mar 10
    		$-0.27$-0.04-575.00%Miss-775.0%
    Sep 21
    Reported Nov 9
    		$0.04$-0.03+233.33%Beat+0.0%
    Jun 21
    Reported Aug 10
    		$0.09$0.04+125.00%Beat+164.3%
    Mar 21
    Reported May 11
    		$0.09$0.02+350.00%Beat+325.0%
    Dec 20
    Reported Mar 8
    		$0.04$0.04+0.00%Beat-60.0%
    Sep 20
    Reported Nov 9
    		$0.04N/A+144.44%Beat+113.8%
    Jun 20
    Reported Aug 10
    		$-0.14$-0.17+17.65%Beat-180.0%
    Mar 20
    Reported May 11
    		$-0.04$-0.02-100.00%Miss+0.0%
    Dec 19
    Reported Mar 13
    		$0.10$0.06+66.67%Beat-87.0%
    Sep 19
    Reported Nov 13
    		$-0.29$-0.04-625.00%Miss-141.7%
    Jun 19
    Reported Aug 14
    		$-0.05$-0.06+16.67%Beat-145.5%
    Mar 19
    Reported May 9
    		$-0.04N/A+66.67%Beat+76.5%
    Dec 18
    Reported Mar 12
    		$0.77$0.34+126.47%Beat+692.3%
    Sep 18
    Reported Nov 13
    		$-0.12$-0.09-33.33%Miss+57.1%
    Jun 18
    Reported Aug 6
    		$0.11$-0.12+191.67%Beat+142.3%
    Mar 18
    Reported May 15
    		$-0.17$-0.16-6.25%Miss+19.0%
    Dec 17
    Reported Mar 8
    		$-0.13N/AN/ABeat+56.7%
    Sep 17
    Reported Nov 14
    		$-0.28$0.00N/ABeat-
    Jun 17
    Reported Aug 10
    		$-0.26$0.00N/ABeat-
    Mar 17
    Reported May 10
    		$-0.21$-0.19-10.53%Miss-
    Dec 16
    Reported Mar 21
    		$-0.30$-0.28-7.14%Miss-

    Key Metrics

    Valuation
    P/E Ratio-59.59EV/EBITDA63.56x
    Price/FCF214.08xFCF Yield0.47%
    Profitability
    Profit Margin-13.50%Operating Margin-15.60%
    ROE-116.10%ROIC-0.85%
    Financial Health
    Debt/Equity19.79xInterest Coverage0.96x
    Current Ratio2.24xQuick Ratio2.08x
    Trading Statistics
    Beta0.18Avg Volume655.59K
    52-Week High$54.8552-Week Low$26.96

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$29.52
    SMA 20$31.04
    SMA 50$35.42
    SMA 200$39.53
    EMA 10$29.45
    EMA 20$30.96
    EMA 50$34.11
    EMA 200$37.54

    MACD

    Line: -2.02Signal: -1.94Hist: -0.08

    ADX

    ADX: 46.2+DI: 10.2-DI: 38.8

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down96.0
    PSAR$30.71

    Bollinger Bands

    Upper Band$35.02
    Lower Band$27.06
    %B Position2564%(Upper)
    Band Width0.21

    RSI (14-Day)

    Neutral
    31.7

    Momentum Oscillators

    Stoch %K17.9
    Stoch %D20.3
    Williams %R-69.8
    ROC (10d)-6.1%
    Momentum-1.86
    CCI (20d)-122.0
    MFI (14d)26.6

    Volatility Measures

    ATR (14d)$1.48(5.2%)
    StdDev (20d)1.99
    Hist Vol36.6%(Moderate)

    Volume Flow

    VWAP$28.23
    OBV-4.3M
    AD Line-9.1M
    CMF (20d)0.007

    Volume Metrics

    Avg Vol (20d)654.3K
    Vol Ratio0.9x
    VWMA (20d)$30.93

    Pivot Points

    R3$29.40
    R2$28.85
    R1$28.05
    Pivot Point$27.50
    S1$26.70
    S2$26.15
    S3$25.35

    Advanced Oscillators

    TSI-47.10
    Ultimate Osc48.9
    KST-180.94

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$70.66M$44.20M$89.09M$71.64M$63.74M$47.83M$66.83M$49.26M$48.94M$34.59M$36.35M$34.27M
    Cost of Revenue$20.30M$17.16M$18.47M$17.71M$16.23M$15.52M$14.13M$12.02M$12.54M$10.55M$11.30M$10.07M
    Gross Profit$50.36M$27.05M$70.62M$53.93M$47.51M$32.31M$52.70M$37.24M$36.40M$24.03M$25.05M$24.20M
    Operating Expenses$61.37M$49.13M$55.03M$39.18M$36.10M$43.54M$39.80M$35.92M$34.87M$30.96M$29.93M$22.45M
    R&D$8.07M$5.89M$11.72M$3.32M$2.87M$3.03M$4.75M$2.27M$3.05M$2.15M$3.34M$1.42M
    SG&A$53.30M$43.23M$43.31M$35.86M$33.23M$40.51M$34.79M$33.65M$31.82M$28.81M$26.21M$21.03M
    Operating Income$-11,007,000$-22,080,000$15.59M$14.75M$11.41M$-11,232,000$12.90M$1.32M$1.53M$-6,928,000$-4,875,000$1.74M
    Interest Income$0$0$0$0$0$0$0$0$-1,923,000$-1,248,000$416,000$1.35M
    Interest Expense$6.26M$5.50M$5.19M$13.79M$6.41M$6.55M$6.38M$5.53M$5.47M$5.42M$5.12M$5.75M
    Income Before Tax$-17,270,000$-27,577,000$10.40M$1.02M$5.00M$-17,780,000$6.26M$-4,200,000$-5,818,000$-13,565,000$-9,683,000$-2,852,000
    Income Tax Expense$0$25,000$0$0$0$0$0$20,000$655,000$0$-535,000$1.54M
    Net Income$-17,270,000$-27,602,000$6.63M$1.02M$5.00M$-17,780,000$6.78M$-4,220,000$-6,473,000$-13,565,000$-9,148,000$-4,391,000
    EBITDA$-4,620,000$-16,045,000$20.72M$20.25M$17.41M$-5,266,000$18.40M$5.07M$5.75M$-2,746,000$-1,104,000$5.67M
    EBIT$-11,007,000$-22,080,000$15.58M$14.81M$11.40M$-11,232,000$12.64M$1.32M$1.58M$-6,902,000$-4,975,000$1.55M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about HROW

    News

    Harrow secures TYRVAYA rights and adds a 2027 test for Harrow Health stock

    Harrow Health (HROW) has acquired worldwide rights to TYRVAYA (excluding Japan) for an upfront payment of USD 30 million and potential milestone payments of up to USD 70 million. This acquisition, completed on October 5...

    ad-hoc-news.de•10/15/26•Bullish

    (HROW) and the Role of Price-Sensitive Allocations

    This article provides an analysis of Harrow Health Inc. (NASDAQ: HROW), highlighting weak sentiment across all time horizons supporting a short bias. It details AI-generated institutional trading strategies...

    Stock Traders Daily•10/12/26•Bearish

    Harrow, Inc. (HROW) stock price, news, quote and history

    This article provides detailed financial information for Harrow, Inc. (HROW), an eyecare pharmaceutical company. It includes stock performance data, key financial metrics, company overview, earnings trends...

    Yahoo Finance Australia•10/11/26•Somewhat-Bearish

    Harrow, Inc. (HROW) stock price, news, quote and history

    This article provides a detailed financial overview of Harrow, Inc. (HROW), an eyecare pharmaceutical company. It includes current stock performance, key financial metrics, an overview of its products and operations...

    Yahoo Finance Singapore•10/9/26•Somewhat-Bearish

    Harrow stock hits 52-week low at 28.51 USD

    Harrow (HROW) stock has fallen to a new 52-week low of $28.51, currently trading just above this floor. Despite an InvestingPro analysis suggesting the stock is oversold and undervalued...

    Investing.com•10/9/26•Bearish

    HROW Valuation and Fair Value

    P/E
    -59.6x
    Forward P/E
    46.7x
    EV/EBITDA
    63.6x
    P/FCF
    214.1x
    P/B
    70.6x
    See GNG's fair value

    HROW Profitability: Margins, ROIC and FCF

    Gross margin
    73.3%
    Operating margin
    -15.6%
    Net margin
    -13.5%
    ROIC
    -0.9%
    ROE
    -116.1%
    FCF margin
    1.8%
    FCF yield
    0.5%

    HROW Competitors

    CompanyTicker
    Opko Health IncOPK
    Castle Biosciences IncCSTL
    Integra LifeSciences HoldingsIART
    Ventyx Biosciences IncVTYX
    HealthStream IncHSTM
    Savara IncSVRA
    Artivion IncAORT
    MannKind CorpMNKD

    Sector: Healthcare

    HROW Analyst Ratings

    Consensus
    Buy
    Analysts
    9
    Strong Buy
    0
    Buy
    9
    Hold
    0
    Sell
    0
    Strong Sell
    0

    HROW Bull Case vs Bear Case

    Bull case

    • HROW grew quarterly revenue 10.9% year over year.
    • 100.0% of HROW's analyst ratings are Buy or Strong Buy.

    Bear case

    • HROW has a -13.5% net profit margin.
    • HROW beat EPS estimates in 37.5% of its last 8 reported quarters.
    • HROW has a debt-to-equity ratio of 19.8x.

    HROW Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -444.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.32
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 3 down

    Frequently Asked Questions About HROW

    Does HROW pay dividends?

    Harrow Health Inc (HROW) does not currently pay a regular dividend.

    What is HROW's market cap?

    Harrow Health Inc (HROW) has a market capitalization of $1.02B with a current stock price of $28.75.

    Related stocks

    Sector: Healthcare

    All stocks starting with H

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In